Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CXCR5-modified EGFR CAR-T in advanced NSCLC
NCT05060796Phase 1Recruiting
- Sponsor
- Second Affiliated Hospital of Guangzhou Medical University
- Start
- Sep 2019
- Primary completion
- Nov 2029
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of CXCR5-modified EGFR chimeric antigen receptor T cells in non-small cell lung cancer (NSCLC), sponsored by Second Affiliated Hospital of Guangzhou Medical University. Primary endpoint: Safety by Common Terminology Criteria for Adverse Events (CTCAE) v5.0 at 52 weeks. Started Sep 2019; status: recruiting.
02
Drugs
CXCR5-modified EGFR chimeric antigen receptor T cells
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT05060796.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05060796.